Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06990048 · ClinicalTrials.gov registry record
The Long-Term EVAR Assessment and Follow-Up (LEAF) Study for the AFX2 System
A clinical trial of Abdominal Aortic Aneurysm, sponsored by Endologix.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT06990048: Recruiting study of Abdominal Aortic Aneurysm, sponsored by Endologix.
NCT06990048 is a study of Abdominal Aortic Aneurysm that is actively recruiting participants, run by Endologix. The registered enrollment target is 2,000 participants, above the 329-participant average among 16 other Abdominal Aortic Aneurysm trials with a reported enrollment target (508% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06990048, a study of Abdominal Aortic Aneurysm, is actively recruiting participants, sponsored by Endologix.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational, retrospective, multicenter study to evaluate the performance of the AFX2 System using real world evidence from VQI-VISION.
Primary Outcome
Rate of the composite of AAA rupture, aortic-related reintervention, and morality through 5 years.
Conditions Studied
Interventions
- DEVICE AFX2 System
Study Locations (1)
New Hampshire
- The Dartmouth Institute - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2027-05 |
What NCT06990048 shows while recruiting
NCT06990048 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 329-participant average among 16 other Abdominal Aortic Aneurysm trials with a reported enrollment target (508% higher).
The record links to 1 condition, with Abdominal Aortic Aneurysm appearing as the primary indexed condition, and to 1 intervention - of which AFX2 System is the first listed.
NCT06990048 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT06990048 about?
NCT06990048 is a clinical study titled "The Long-Term EVAR Assessment and Follow-Up (LEAF) Study for the AFX2 System". This is an observational, retrospective, multicenter study to evaluate the performance of the AFX2 System using real world evidence from VQI-VISION.
What is the current status of trial NCT06990048?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2023-09-21. Estimated completion is 2027-05.
What conditions does trial NCT06990048 study?
This clinical trial studies the following conditions: Abdominal Aortic Aneurysm.
What interventions are being tested in trial NCT06990048?
The interventions under investigation include: AFX2 System (DEVICE).
Who is sponsoring clinical trial NCT06990048?
This trial is sponsored by Endologix, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06990048 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Abdominal Aortic Aneurysm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06990048's enrollment target sits among peer trials
2,000 1st of 16 higher than 16 of 16 other Abdominal Aortic Aneurysm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Abdominal Aortic Aneurysm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Terumo Aortic Global Endovascular Registry
RECRUITING
-
Limiting AAA With Metformin (LIMIT) Trial
RECRUITING · Phase 2
-
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
RECRUITING · NA
-
Nectero EAST System Clinical Study
RECRUITING · Phase 2
-
PET Imaging of MMP Activation in AAA: Clinical Component
RECRUITING · Early Phase 1
-
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI